Back to School: How biopharma can reboot drug development. Access exclusive analysis here

UroGen other research news

UROG received a 2-year $500,000 Phase

Read the full 68 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE